Transcriptomics in Atherosclerosis : Deciphering Molecular Signatures and Advancing Therapeutic Strategies

• Unravels the molecular complexity of atherosclerosis using the latest transcriptomic technologies, offering new perspectives on disease mechanisms and potential therapeutic targets
• Highlights the transformative potential of RNA molecules in advancing diagnostics and developing novel RNA-based treatments for personalized medicine in cardiovascular care
• Provides actionable insights into translating transcriptomic findings into clinical applications, enhancing patient stratification and treatment strategies

Yvan Devaux, Ph.D. explores the frontiers of RNA biology in cardiovascular and neurological disease. With a translational, patient-centered approach, his work bridges disciplines―uniting clinicians, computational biologists, researchers, and industry partners to address urgent medical needs. Devaux’s team has pioneered biomarker discovery pipelines using deep sequencing, AI, and advanced bioinformatics. A seasoned leader of large-scale research consortia, he now focuses on the heart-brain axis, uncovering RNA biomarkers that illuminate the complex interplay between brain and heart disease. This volume captures his vision for collaborative, data-driven innovation in precision medicine.

Miron Sopić, Ph.D. is an Associate Professor of Medical Biochemistry at the Faculty of Pharmacy, University of Belgrade. He teaches biochemistry with a strong emphasis on its diagnostic applications, grounded in his scientific expertise. His research centers on inflammation in cardiometabolic diseases, particularly the discovery of RNA-based biomarkers. Dr. Sopić is the author of more than 54 scientific publications and was awarded the Marie Skłodowska-Curie Postdoctoral Fellowship in 2022. This fellowship enabled his collaboration with Dr. Yvan Devaux at the Luxembourg Institute of Health, where they are exploring epitranscriptomic signatures in atherosclerosis―pushing the boundaries of cardiovascular molecular medicine.